Press

Elpis Biopharmaceuticals NCCS

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 27, 2025 /PRNewswire/ — Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with […]

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore Read Post »

Press
Monster Energy Magomedov v Barriault

Monster Energy’s Shara “Bullet” Magomedov Defeats Marc-André Barriault at UFC Fight Night in Abu Dhabi

31-Year-Old from Makhachkala, Russia Earns Unanimous Decision Victory in Middleweight Fight, Earns UFC’s $50,000 Fight of the Night Bonus ABU DHABI, UAE, July 27, 2025 /PRNewswire/ — The “Bullet” is back on track! Monster Energy congratulates MMA athlete Shara Magomedov on defeating Marc-André Barriault at the UFC Fight Night in Abu Dhabi on Saturday night. In

Monster Energy’s Shara “Bullet” Magomedov Defeats Marc-André Barriault at UFC Fight Night in Abu Dhabi Read Post »

Press

CNC Investors with Losses Have Opportunity to Lead Centene Corporation Securities Fraud Lawsuit

NEW YORK, July 27, 2025 /PRNewswire/ —  Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has

CNC Investors with Losses Have Opportunity to Lead Centene Corporation Securities Fraud Lawsuit Read Post »

Press

RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 27, 2025 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for

RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Read Post »

Press

RMJAX, RMHIX, RMHVX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Easterly ROCMuni High Income Municipal Bond Fund Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 27, 2025 /PRNewswire/ — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (“Easterly ROCMuni Fund” or “the Company”) (NASDAQ: RMJAX, RMHIX, RMHVX) and certain of its

RMJAX, RMHIX, RMHVX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Easterly ROCMuni High Income Municipal Bond Fund Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Read Post »

Press

CNC INVESTOR ALERT: Centene Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

SAN DIEGO, July 27, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene and certain of Centene’s executives with violations

CNC INVESTOR ALERT: Centene Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit Read Post »

Press
LuminEyes Light Therapy Device

Breakthrough in Light Therapy: KouShiCare utilizes DWV™LLLT Technology to Treat Dry Eyes

HONG KONG, July 27, 2025 /PRNewswire/ — KouShiCare, a leading innovator in healthcare technology, is proud to announce a groundbreaking advancement in the treatment of dry eye disease. The company’s latest device harnesses the power of DWV™ Low-Level Laser Therapy (LLLT) technology, marking a significant step forward in light-based ocular care. Approximately 344 million people

Breakthrough in Light Therapy: KouShiCare utilizes DWV™LLLT Technology to Treat Dry Eyes Read Post »

Press
Scroll to Top